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Cirrhosis is associated with disabling symptoms and diminished health-related quality of life 
(HRQOL). However, for patients with compensated disease, data are limited regarding 
associations with poor patient-reported outcomes (PROs). We prospectively enrolled 300 
patients with cirrhosis and portal hypertension without a history of hepatic encephalopathy and 
reviewed medical and pharmacy records. We characterized determinants of PROs using the SF-8 
scale (0-100) and sleep quality using the Pittsburgh Sleep Quality Index (poor sleep >5). 
Disability and frailty measures were assessed using Activities of Daily Living (ADL), falls, 
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inhibitory control test [ICT]. The mean age of our cohort was 60 IQR (52-66) years, 56.3% were 
male, and 70% Child Class A. All patients had portal hypertension, 76% had varices and 41% 
had a history of ascites (predominantly well controlled). The median MELD-Na was 9 (IQR 7–
13). The overall median SF-8 was 75 (59-86). Multivariate analysis showed that adjusting for 
age, sex, education, and MELD-Na, performance on chair-stands (9.28 HRQOL points (95% CI 
4.76-13.8) per 10-stands), ADL dependence (-6.06 (-10.8- -1.36)), opiate use (-5.01 (-7.84- -
2.19)), benzodiazepine use (-3.50 (-6.58- -0.42)), and ICT performance (-0.10 (-0.20 – 0.001) per 
weighted-lure) were significantly associated with HRQOL. Among patients completing the ICT, 
poor HRQOL (score<50) was significantly associated with chair-st nds (odds ratio per 10-
stands, 0.24 95%CI[0.11-0.56]) and weighted lures (OR per weighted-lure, 1.01 [1.00-1.03]). 
Poor sleep quality was associated with opiate use (OR 2.85 95%CI[1.11-7.29] and lures (OR per-
lure, 1.03 [1.00-1.05]). 
Conclusion: Disability, chair-stand performance, cognitive dysfunction, as well as psychoactive 




Cirrhosis is the final common pathway for most chronic liver diseases.(1) The majority of 
the >630,000 patients with compensated cirrhosis in the United States (US) live more than a 
decade after diagnosis making compensated cirrhosis a chronic condition.(2) Mortality markedly 
increases with the onset of complications such as ascites, variceal hemorrhage and hepatic 
encephalopathy (HE). In addition to clinical decompensations, cirrhosis is also associated with 
poor patient reported outcomes (PROs) such as poor sleep and iminished health-related quality 
of life (HRQOL). We recently reviewed the determinants of PROs in cirrhosis.(3) Like others, 
we found that liver disease severity, particularly HE, is the principal driver of symptoms and 
poor HRQOL.(4-8) Adequate control of cirrhosis complications is therefore crucial to improving 
PROs.(6) Less is known, however, regarding the determinants of and targets for improvements 
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In order to study the incidence and predictive factors of overt HE and to test interventions 
that might improve PROs in patients with cirrhosis, we enrolled 300 patients with cirrhosis and 
portal hypertension but no prior HE to characterize the determinants of their PROs in search of 
potentially modifiable factors.  A priori, we were interested in psychoactive medications and 
frailty. Psychoactive medications are frequently used,  have unique adverse effects in patients 
with cirrhosis,(9) and can often be substituted for equally effective alternative therapies that do 
not have the sedating side- ffects.(10-12) Indeed, in a nationally representative study of patients 
with noncancer chronic pain propensity matched for opiate use, opiates were not associated with 
improved pain or significantly different PROs.(13) Similarly, frailty is also common among 
patients with cirrhosis, associated with poor PROs, and in some patients may be reversed with 
nutrition and physical therapy.(14-17)  
Methods 
 We prospectively enrolled 300 subjects from the Hepatology subspecialty clinic of the 
University of Michigan Health System from July 2017 to April 2018. Patients were identified by 
a manual search of clinical schedules for all adults >18 years of age with a diagnosis of cirrhosis 
and portal hypertension based on clinical, histological and radiographic data. In the absence of a 
liver biopsy, patients had to meet at least 2 of the following criteria: imaging findings of cirrhosis 
(cirrhotic appearing liver, splenomegaly, varices, ascites), ransient elastography >13 kPa, 
aspartate aminotransferase (AST)/platelet ratio index (APRI) >2.0, and endoscopy with presence 
of esophageal varices. The presence of portal hypertension was defined by at least 1 of the 
following: ascites, hydrothorax, varices or history of variceal hemorrhage, platelet count < 80K 
(in the absence of hematological causes of thrombocytopenia). We excluded all patients with 
Child C cirrhosis, a current or past history of overt hepatic encephalopathy (HE) (history of 
hospitalization for HE, current lactulose or rifaximin prescription), non-English speaking, 
estimated life expectancy <12 months, pregnancy, severe mobility impairment (e.g. 
hemiparesis), severe cognitive impairment (including overt HE), prior liver transplantation, or 
history of transjugular intrahepatic portosystemic shunt placement. This study utilizes baseline 
assessment of patients enrolled in a longitudinal cohort study aimed to determine incidence and 
predictors of overt HE. As such patients with overt HE at enrollment were excluded. W 
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sustained virologic response at the time of enrollment. This study was approved by the 
University of Michigan Health System Institutional Review Board and all subjects provided 
written informed consent. 
 
Screening and Recruitment 
Overall, 814 patients were eligible, 360 were not recruited due to being missed in clinic 
or not attending scheduled visits, 150 were approached but declined participation (66 were 
interested but did not have time to complete the study procedures, 58 refused, and 26 were found 
to be ineligible due to a new diagnosis of HE ascertained by a hepatologist during their clinic 
visit), and 4 were enrolled in error due to a remote history of HE.  
 
Outcomes 
The primary outcome was HRQOL as measured by the Short-Form 8. Each patient’s 
HRQOL was denoted by a summary score that w s an average of all domains. (See 
Supplementary Methods). The advantage of the SF-8 over the SF-36 is that it is shorter, and it 
has been studied in patients with chronic liver disease.(18-20) We evaluated absolute HRQOL 
score (0-100, scored according to RAND methods(21)) and  dichotomy of scores into 
satisfactory and poor HRQOL defined as score <50.(22)  
 
Sleep quality was evaluated as a secondary outcome. All patients completed the 
Pittsburgh Sleep Quality Index (PSQI), a widely validated tool.(23) The PSQI has been 
extensively studied in patients with cirrhosis. (8, 24) It is strongly correlated with HRQOL and 
depression (patients with depression have similar HRQOL scores as those with sleep 
disorders(23)), in part because the PSQI measures symptoms of poor HRQOL and depression 
(i.e. pain, anxiety, enthusiasm) and also because poor sleep leads to poor HRQOL. The PSQI has 
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An interview was at the time of enrollment to collect da a regarding demographics, 
clinical history, current daily-use medications, and comorbidities (Charlson Comorbidity 
Index(25). Alcohol use over the prior 12 months was recorded using a validated 
questionnaire.(26) Alcohol abuse was defined by binge drinking (>5 drinks in 2 hours, >4 for 
women) or chronic use >7 or >14 drinks/week for women and men, respectively. Medication 
lists were reconciled at the time of the visit. Chronic medication use was defined as > 90 days of 
use. We specified a distinction between tricyclic antidepressants and conventional anti-
depressants because the indication for these medication classes typically differ. Severity of liver 
disease was assesd using the Child Classification and Model for Endstage Liver Disease with 
Sodium (MELD-Na).  
 
Functional disability was assessed by Katz Activity of Daily Living (ADL) scale.(27) All 
patients were questioned about any history of falls over the prior 6 months. A physical frailty 
assessment was performed using two tests. Hand grip strength was evaluated using a hand-held 
dynamometer, patients were asked to squeez  the device three times with their dominant hand. 
The force of each squeeze was recorded, and the best result retained for analysis. Frail 
performance was defined with respect to sex and body-mass index (Supplementary 
Methods).(16) The number of chair stands (repeatedly rising from a seated position to standing 
and sitting again) performed within 30 seconds was also assessed Du  to lack of standard 
definitions, frail performance was defined as t-score < -1.0 (in this case, <5 chair stands in 30 
seconds), consistent with the definition used by Lai et al.(16)  
Cognitive testing was performed using the inhibitory Control Test (ICT), a validated, 
free-to-use, computerized test developed by Bajaj et al, which takes 10-15 minutes to 
complete.(28) The subject is asked to respond to cues as they are flashed on a computer screen 
(see example in appendix). The number of incorrect responses (called ‘lures’) is automatically 
tabulated by the computer program to determine the test results. As established by Amodio et 
al,(29) we also adjusted the lures for the number of correct responses (called ‘targets’). 
Weighted-lures are calculated as follows: lures/(proportion of targets met2); Amodio showed that 




















 Comparisons of continuous variables were performed using Student’s T test and 
Wilcoxon Rank Sums tests for parametric and non-parametric variables, respectively. 
Categorical variables were compared using a Chi-Squared test. To evaluate the primary outcome, 
we performed linear regression. We also performed a logistic regression for dichotomous 
HRQOL (<50 as poor) and the secondary outcome (PSQI >5). Univariable associations with p-
values <0.05 were included in multivariable regressions. Given the importance of age, sex, and 
MELD-Na in both quality of life estimates and the interpretation of many covariates (e.g. hand-
grip), these variables were included in all multivariable models. An estimate of model 
performance was provided using the coefficient of determination (or R2 
 
value), a measure of 
goodness of fit that ranges from 0 to 1 (perfect fit). Many patients could not complete the ICT, 
limiting multivariable regressions that include cognitive performance. Rather than impute 
missing values, we performed sensitivity analyses for our regressions omitting ICT performance. 
Finally, we re-evaluated model estimates in clinically relevant subgroups, namely patients with 
compensated (Child A) cirrhosis, prior/current ascites or diuretic use, cured HCV, those without 
a history of alcohol abuse, and those without prescriptions for opiates or benzodiazepines. The 
sample size of 300 was determined for the primary outcomes of our longitudinal study aimed to 
determine predictors of incident overt HE. Power calculation was not performed for the current 
analysis on PROs at enrollment and associated factors. All analyses were performed using JMP 
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Demographics and Clinical Factors 
 Characteristics of our 300 enrolled patients are delineated in Table 1. Mean age was 60 
years, 56% were male, median years of education was 14, 70% were Child Class A and median 
MELD-Na was 9. All patients had portal hypertension including 76% with varices, 41% with a 
history of ascites (10% requiring paracentesis), and 37% with thrombocytopenia (<80,000).  
 
Frailty and Cognitive Function 
 Most patients (91%) were able to carry out all their ADLs independently. Compared to 
men, women had significantly lower hand-grip (22.8+7.3 vs 38.5+12.4 kg, p<0.0001) but not 
chair-stands (10.0+5.4 vs 9.9+5.5, p=0.87). Proportion of women and men with a history of falls
within the last six months was similar, 32(24%) vs 33(20%), p=0.33. Ninety-one (34%) patients 
had impaired cognitive function based on ICT weighted lure values. Overall cognitive 
performance measured as lures, targets, or weighted lure values were not different with respect to 
sex, Child class, benzodiazepine or opiate use, alcohol abuse, or alcohol vs other causes of 
cirrhosis (Table 1). Of note, 37 (12.3%) patients could not perform the ICT; 22 became 




Associations with Quality of Life 
  The median SF-8 score for HRQOL was 70 (interquartile range 54-86) with 59 (20%) 
reporting scores <50. Figure 1 shows the average raw SF-8 score for the entire cohort and 
subgroups. In Table 2, we show that HRQOL was associated with education, etiology of liver 
disease (alcohol-related), severity of liver disease (Child class B, MELD-Na), use of 
psychoactive medications (antidepressants, opiates, benzodiazepines, and gabapentin), frailty 
(ADL performance, chair-stands, and falls) and cognitive function (weighted-lures). When we 
adjusted these results for each other (with forced inclusion of age, sex and MELD-Na), the 
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benzodiazepine use, opiate use, and weighted-lures. This final model had an R2 of 0.36, 
suggesting that it explained a substantial (36%) portion of the variance in quality of life in our 
cohort. For comparison, the respective univariable R2
 
 associated with MELD-Na, education, 
chair-stands, ADL dependence, benzodiazepine use, opiate use, and weighted-lures was 0.02, 
0.03, 0.15, 0.07, 0.07, 0.03, and 0.04. 
 In Supplementary Table 1, we performed a logistic regression conditioned on poor 
HRQOL (SF-8 score <50). In this analysis, only chair-stands (odds ratio [OR] per 10-stands 0.24 
95%CI[0.11-0.56]) and weighted lures (OR per weighted-lure 1.01 [1.00-1.03]) were 
significantly associated with poor HRQOL. In a sensitivity analysis excluding ICT performance, 
chair-stands (OR 0.34 95%CI[0.17-0.72]) and falls (2.20 [1.06-4.59]) were associated with poor 
HRQOL. 
 
Quality of Life in Clinically Important Subgroups 
 In Figure 1 and Table 3, we demonstrate model estimates in subgroups relevant to 
clinical practice. Only opiate use was consistently associated with poor HRQOL across 
subgroups. Chair-stands, a measure of frailty, was associated with HRQOL in all groups save for 
those with ascites or diuretic use. A history of ascites, when present, was an over-riding 
determinant of HRQOL. The magnitude of the association between chair-stands and HRQOL 
was substantially greater for patients with Child A cirrhosis (severity of liver disease was an 
over-riding determinant of HRQOL in those with Child B cirrhosis). Cognitive functio , as 
measured by weighted-lures, was associated with HRQOL only in patients with cured hepatitis 
C, no prior alcohol abuse, and those not on opiates or benzodiazepines. 
 
Associations with Poor Sleep 
 Our patients reported a median PSQI score of 7 IQR (4-11), 187 (63%) of whom had 
poor sleep (PSQI>5). Although poor sleep was highly prevalent, we show that specific 
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with Child B cirrhosis (71.4%), those with weak chair-stand performance (84.1%), and users of 
opiates and benzodiazepines (87.0%). We excluded benzodiazepines from regression analyses 
given that they are often used explicitly for poor sleep. Many factors that were strongly 
associated in a univariate analysis including l ver disease severity and frailty were not significant 
in multivariable analysis. In Supplementary Table 2, we detail the results of a multivariable 
logistic regression that found only 2 factors were significantly associated with poor sleep: opiate 
use (OR 2.85 95%CI[1.11-7.29] and weighted lures (1.03 [1.00-1.05]). In a sensitivity analysis 
excluding ICT performance, \opiates (2.23 [1.04-4.78]), Child B (2.11 [1.16-3.82]), and chair-





The lived experience of cirrhosis can be very challenging for many patients, marked by 
debilitating symptoms and poor HRQOL.(3) Poor PROs have been traditionally associated with 
cirrhosis complications such as ascites and overt HE.(4-8) However, this prospective study of 
300 generally clinically stable outpatients with cirrhosis, half of whom had no history of 
decompensation and none had history of overt HE, highlight other, potentially modifiable targets
for suboptimal PROs. Specifically, we found that markers of frailty, psychoactive medications, 
and cognitive function were associated with HRQOL and sleep quality.  
 
These data come at an important time in the history of chronic liver disease. The 
prevalence of cirrhosis is rising due to the increasing prevalence of non-alcoholic fatty liver 
disease (NAFLD) and alcohol-related liver disease.(30, 31) At the same time, as we approach the 
eradication of hepatitis C, we expect to arrest the natural history of cirrhosis for many patients, 
extending lives substantially. Thus, more patients are living with cirrhosis and will be living 
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A conceptual model of quality of life in cirrhosis with portal hypertension 
 Adjusting for severity of liver disease, age, and education, we found associations with 
HRQOL and poor sleep quality that extend current knowledge in important ways. First, several 
studies have shown that frailty is common and associated or correlates with poor quality of life in 
patients with end-stage liver disease.(32, 33) Our data showed that this is also true in a 
population with earlier-stage cirrhosis, highlighting the importance of recognizing and managing 
frailty across the stages of cirrhosis. The relationship between frailty and poor HRQOL is likely 
complex; although muscle weakness may interfere with activities it may also reflect qualitatively 
more severe comorbidities and cognitive dysfunction. The association between chair-stands and 
poor sleep underscores that frailty reflects a global disorder that impacts PROs beyond physical 
function.  
 
Second, we found that impaired cognitive function as measured by ICT performance is 
associated with poor HRQOL. The ICT has been used for diagnosis of covert HE.(34) Nabi et al 
previously exploited the relationship between covert HE and poor HRQOL and showed that a 4-
question modification of the Sickness Impact Profile HRQOL-tool, can be used to indicate risk 
for, if not diagnose, covert HE.(35) Our data showed that ICT performance can also identify 
patients with poor HRQOL. However, we found that impaired cognitive function had a greater 
impact on HRQOL in patients with neither alcohol abuse histories nor psychoactive medication 
use. As we have reviewed elsewhere,(36) the ICT, like other tests of covert HE, has not been 
validated in patients with alcohol abuse or those on psychoactive medications. For this important 
subset of patients, alcohol, opiate or benzodiazepine use may diminish their ability to carry out 
these tests and confound the results. Indeed, we found that an important subgroup of patients 
could not perform the ICT. In order to assess associations with ICT scores this this subgroup,  
must be excluded, thereby masking associations between poor sleep quality, psychoactive 
medications, and frailty. 
 
Third, we showed that chronic opiate and benzodiazepine use is common in patients with 















This article is protected by copyright. All rights reserved 
extend results from Ghabril et al who demonstrated an impact of opiates on HRQOL and sleep 
quality in patients with decompensated cirrhosis.(8) We acknowledge that poor HRQOL in these 
patients may be driven by the indications for opiate or benzodiazepine use and not necessarily a 
direct effect of these medications in patients with cirrhosis.(37) However, these medications are 
well-recognized to have adverse effects inpatients with cirrhosis and can often be substituted for 
safer therapies without worsening symptoms and other PROs.(10, 13)  
 
Targets for future action 
 Our cross-sectional data highlight three paths for future studies aimed at improving PROs 
through multimodal interventions that reduce the adverse effects of polypharmacy, address 
cognitive dysfunction, and improve physicality/frailty. First, though these data cannot 
disentangle the effect of psychoactive medications from confounding by indication, their 
association with HRQOL justifies a prospective trial of de-pr scribing. Psychoactive medications 
such as opiates or benzodiazepines can often be discontinued or substituted with non-
pharmacologic treatments (e.g. talk-therapy for anxiety, sleep-hygiene training for insomnia, 
physical therapy for back pain), avoiding side-effects without therapeutic failure and may even 
improve quality of life.(10, 38) In addition to the potential value in improving HRQOL, there is a
physiological rationale for de-prescribing psychoactive medications in patients with cirrhosis. 
Benzodiazepines sedate while potentiating inhibitory (GABAergic) tone; piates sedate while 
decreasing intestinal motility, potentially increasing the absorption of ammonia a d bacterial 
translocation.(9) These mechanisms are both implicated in HE.In light of the recent opioid 
epidemic, many studies been conducted to evaluate the efficacy of alternative, less addictive 
approaches to pain control in non-oncology settings showing similar effectiveness. Although 
worsened HRQOL is a theoretical risk after opiate discontinuation, the available data actually 
supports withdrawal.(10, 13) These data support a position of clinical equipoise and justify 
similar clinical trials in patients with cirrhosis.  
 Second, by identifying patients with sub-optimal performance on cognitive testing, we 
may initiate therapeutic trials – including lactulose or rifaximin – that could have the potential to 
improve quality of life.(7) Third, interventions for patients with frailty such as improved 
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These interventions have b en shown to be effective in improving HRQOL in patients with 
advanced cirrhosis on the liver transplant waiting list but have not been studied in patients with 




 Our data must be interpeted in the context of the study design. First, this cross-sectional 
analysis cannot establish causation. Our data are at risk for confounding by indication (pain and 
anxiety for which psychoactive medications are prescribed are also linked with poor HRQOL). 
Second, our cohort best reflects the characteristics of patients seen at a tertiary referral center and 
may not generalize to ther patients with cirrhosis.  
 
Conclusions 
 Deficits in quality of life are present even in patients with predominantly Child A
cirrhosis. These findings underscore the need for a holistic assessment of our patients and 
highlight opportunities to improve PROs in patients with cirrhosis. Our data support the role for 
a multifactorial intervention aimed at reducing polypharmacy, improved physical function, and 
testing-and-treating of cognitive dysfunction. 
FIGURE LEGENDS 
 
Figure 1: Health-related Quality of Life (HRQOL) and Sleep Quality in Population 
Subgroups  
Left side: Each bar displays the median (interquartile range) SF-8 score for sample subgroups. 
ADL = activities of daily living. High SF-8 score indicates better quality of life.  
Right side: Each bar displays the proportion of patients with Pittsburgh Sleep Quality Indices > 5 




















Table 1: Characteristics of the 300-person Cohort at Enrollment 
Age, years  60 (52-66) 
Education, years  14 (12 – 16)  
Sex, male  169 (56.3%) 
Body Mass Index, kg/m 29 (26 – 34) 2 
Etiology* 
    Hepatitis C 
    Alcohol 
    NAFLD 





Hepatocellular Carcinoma  22 (7.3%) 
Child class A   208 (70%) 
Varices 229 (76%) 
Ascites 122 (41%) 
Platelet count < 80, 00 111 (37%) 
Any current alcohol use  92 (31%) 
Current alcohol abuse  22 (7.3%) 
Charlson Comorbidity Index 4 (1 – 4) 
Laboratory Values  
MELD-Na  9 (7 – 13) 
Bilirubin (mg/dL) 1 (0.7 – 1.6) 
Creatinine (mg/dL) 0.9 (0.7 – 1.04) 
INR  1.1 (1 – 1.2) 
Sodium (meq/L) 140 (138 – 141) 
Albumin  (mg/dL) 4 (3.6-4.3) 
Markers of Frailty   
Incompletely independent in ADLs  27 (9%) 
Chair stands  10 (7- 13) 
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Self-reported falls in past 6 months 65 (22%) 
Medication Reconciliation (chronic current use)  
Diuretics 120 (40%) 
Nonselective Beta-blockers 180 (60%) 
Proton pump inhibitor  128 (43%) 
Benzodiazepine  55 (18%) 
Gabapentin/Pregabalin  45 (15%) 
Opiate  67 (22%) 
Antidepressant  54 (18%) 
Antipsychotic 21 (7%) 
Inhibitory Control Test Performance  
Lures  12 (7 -22) 
Targets 94.3 (84 – 98) 
Weighted lures 14.5 (8.2 – 37.8) 
Cannot complete ICT  39 (13%) 
Categorical values are presented as number and percent. Continuous variables are presented as median (interquartile range). ICT 
= inhibitory control test, INR = international normalized ratio, MELD-Na = Model for Endstage Liver Disease with Sodium, 
NAFLD = Nonalcoholic Fatty Liver Disease. *some patients had both hepatitis C and alcohol-related liver disease 
 
Table 2: Univariate and Multivariate  Associations with Quality of Life 
 Univariate Analysis Multivariate Analysis 
 Effect Estimate (95% 
Confidence Interval) 




Age (per year) 0.16 (-0.05 – 0.36) 0.13   
Education (per year) 1.33 (0.13 – 2.52) 0.03 1.09 (0.10–2.09) 0.03 
Male -0.88 (-3.54 – 1.78) 0.52   
Body Mass Index (per point) -0.47 (-0.87 - -0.06) 0.02 -0.16 (-0.52-0.19) 0.36 
Charlson Comorbidity (per 
point) 
-0.59 (-1.36 – 0.18) 0.13   
Hepatitis C 
ALD 
-1.06 (-7.24 – 5.12) 
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NAFLD -1.98 (-8.90 – 4.93) 0.57 
Hepatocellular Carcinoma 0.70 (-4.77 – 6.18) 0.80   
Child class B -3.81 (-6.72 - -0.89) 0.01 -0.49 (-3.60-2.62) 0.75 
Varices -0.70 (-3.88 – 2.48) 0.67   
Ascites -1.19 (-3.87 – 1.50) 0.38   
Platelet count < 80, 00 -2.64 (-5.39 – 0.11) 0.06   
Alcohol abuse -0.72 (-5.73 – 4.28) 0.78   
MELD-Na (per point) -0.66 (-1.02 - -0.19) 0.008 -0.40 (-0.90– 0.09) 0.11 
Bilirubin (per mg/dL) -2.40 (-4.14 - -0.67) 0.007   
Creatinine (per mg/dL) 0.57 (-2.61 – 3.76) 0.72   
INR (per point) -12.0 (-21.5 - -2.63) 0.01   
Sodium (per meq/L) 0.26 (-0.02 – 0.53) 0.06   
Albumin (per mg/dL) 6.54 (1.87 – 11.2) 0.006 2.20 (-3.03-7.43) 0.41 
Falls -8.16 (-11.4 - -4.95) <0.0001 -2.69 (-0.19- 5.57) 0.07 
Chair stands (per 10 stands) 11.40 (9.40 – 18.60) <0.001 9.28 (4.76-13.8) <0.0001 
Hand grip (per 10 kilograms) 1.90 (-0.10 – 3.90) 0.06   
ADL dependence -9.46 (-14.8 - -4.08) 0.0006 -6.06 (-10.8- -1.36) 0.01 
Diuretics -1.20  (-3.68 – 1.28) 0.34   
Nonselective Beta-blockers -0.79 (-3.27 – 1.69) 0.53   
Proton Pump Inhibitor -3.27 (-5.93 – -0.60) 0.02 1.17 (-1.23 – 3.57) 0.34 
Benzodiazepine -6.17 (-9.79 - -2.54) 0.0009 -3.50 (-6.58- -0.42) 0.03 
Gabapentin -5.79 (-9.35 - -2.23) 0.002 -1.81 (-5.02-1.40) 0.27 
Opiate -10.4 (-13.5 - -7.30) <0.0001 -5.01 (-7.84- -2.19) 0.0006 
Tricyclic Antidepressant -4.90 (-8.88 – 0.92) 0.02 -1.40 (-5.34 -2.55) 0.49 
Antidepressant -6.39 (-9.88 - -2.90) 0.0004 -3.01 (-6.47 – 0.46) 0.09 
Antipsychotic -4.96 (-9.96 – 0.04) 0.05   
ICT Lures (per lure) -0.21 (-0.46 – 0.04) 0.10   
ICT Targets (per target) 0.11 (-0.09 – 0.31) 0.26   
Weighted lures (per point) -0.14 (-0.26 - -0.02) 0.04 -0.10 (-0.20 – 0.001) 0.049 
The estimates reflect the results of a linear regression and should be interpreted as a positive or a negative effect on quality of 
life. The multivariable analysis included all variables with p <0.05 in the univariable analysis. We also included age, sex, and 
Child Class given the biologic association of these variables with the other candidate covriates. We did not include bilirubin or 
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Table 3: Correlates of Health-Related Quality of Life  (HRQOL)  in Subgroups 
Covariate Child A (n=208) Ascites or diuretics 
(n = 143) 
Cured Hepatitis C  
(n = 91) 
No current or prior 
alcohol abuse (n = 232) 
No current opiate 
or benzodiazepine 
use (n = 202) 
Chair stands  
(per 10 stands) 
13.1 (7.27 – 18.90)  7.92 (0.26 – 15.6) 7.99 (3.24 – 12.73) 9.52 (4.40 – 14.63) 
Opiate Use  
(yes vs no) 
-4.90 (-8.29- -1.50) -6.62 (-10.7 - -2.53 -5.50 (-10.9 - -0.13) -5.17 (-8.36 - -1.98)  
MELD-Na 
(per point) 
 -0.77 (-1.36 - -0.18)   -0.68 (-1.13 - -0.22) 
Antidepressants 
(yes vs no) 
 -4.24 (-8.31 - -0.18)    
Weighted Lures 
(per point) 
  -0.16 (-0.32 - -
0.006) 
-0.13 (-0.23 - -0.02) -0.17 (-0.28 - -0.06) 
Incomplete ADLs 
(yes vs no) 
   -4.81 (-9.24 - -0.38) -5.84 (-10.6 - -1.11) 
Benzodiazepines 
(yes vs no) 
   -4.14 (-7.57 - -0.71)  
HRQOL is scored on a scale from 0-1 0. Results of the multivariable model from Table 2 for subgroups. Only the significant resul s are depicted 
for each subgroup. Each estimate is the result of a linear regression with a 95% confidence interval, indicating a positive or a negative impact on 
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